353 related articles for article (PubMed ID: 12210731)
21. Role of the RANKL/RANK system in the induction of interleukin-8 (IL-8) in B chronic lymphocytic leukemia (B-CLL) cells.
Secchiero P; Corallini F; Barbarotto E; Melloni E; di Iasio MG; Tiribelli M; Zauli G
J Cell Physiol; 2006 Apr; 207(1):158-64. PubMed ID: 16270354
[TBL] [Abstract][Full Text] [Related]
22. The ratio of messenger RNA levels of receptor activator of nuclear factor kappaB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis.
Fazzalari NL; Kuliwaba JS; Atkins GJ; Forwood MR; Findlay DM
J Bone Miner Res; 2001 Jun; 16(6):1015-27. PubMed ID: 11393778
[TBL] [Abstract][Full Text] [Related]
23. Long wave ultrasound may enhance bone regeneration by altering OPG/RANKL ratio in human osteoblast-like cells.
Maddi A; Hai H; Ong ST; Sharp L; Harris M; Meghji S
Bone; 2006 Aug; 39(2):283-8. PubMed ID: 16567138
[TBL] [Abstract][Full Text] [Related]
24. Microrough implant surface topographies increase osteogenesis by reducing osteoclast formation and activity.
Lossdörfer S; Schwartz Z; Wang L; Lohmann CH; Turner JD; Wieland M; Cochran DL; Boyan BD
J Biomed Mater Res A; 2004 Sep; 70(3):361-9. PubMed ID: 15293309
[TBL] [Abstract][Full Text] [Related]
25. Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor.
Zannettino AC; Holding CA; Diamond P; Atkins GJ; Kostakis P; Farrugia A; Gamble J; To LB; Findlay DM; Haynes DR
J Cell Physiol; 2005 Aug; 204(2):714-23. PubMed ID: 15799029
[TBL] [Abstract][Full Text] [Related]
26. Synovial dendritic cells in juvenile idiopathic arthritis (JIA) express receptor activator of NF-kappaB (RANK).
Varsani H; Patel A; van Kooyk Y; Woo P; Wedderburn LR
Rheumatology (Oxford); 2003 Apr; 42(4):583-90. PubMed ID: 12649407
[TBL] [Abstract][Full Text] [Related]
27. Cytokine pattern determines the progression of experimental periodontal disease induced by Actinobacillus actinomycetemcomitans through the modulation of MMPs, RANKL, and their physiological inhibitors.
Garlet GP; Cardoso CR; Silva TA; Ferreira BR; Avila-Campos MJ; Cunha FQ; Silva JS
Oral Microbiol Immunol; 2006 Feb; 21(1):12-20. PubMed ID: 16390336
[TBL] [Abstract][Full Text] [Related]
28. OPG, RANK and RANK ligand expression in thyroid lesions.
Heymann MF; Riet A; Le Goff B; Battaglia S; Paineau J; Heymann D
Regul Pept; 2008 Jun; 148(1-3):46-53. PubMed ID: 18367263
[TBL] [Abstract][Full Text] [Related]
29. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease.
Sattler AM; Schoppet M; Schaefer JR; Hofbauer LC
Calcif Tissue Int; 2004 Jan; 74(1):103-6. PubMed ID: 14523602
[TBL] [Abstract][Full Text] [Related]
30. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients.
Kotake S; Udagawa N; Hakoda M; Mogi M; Yano K; Tsuda E; Takahashi K; Furuya T; Ishiyama S; Kim KJ; Saito S; Nishikawa T; Takahashi N; Togari A; Tomatsu T; Suda T; Kamatani N
Arthritis Rheum; 2001 May; 44(5):1003-12. PubMed ID: 11352231
[TBL] [Abstract][Full Text] [Related]
31. Expression of inflammatory cytokines, RANKL and OPG induced by titanium, cobalt-chromium and polyethylene particles.
Masui T; Sakano S; Hasegawa Y; Warashina H; Ishiguro N
Biomaterials; 2005 May; 26(14):1695-702. PubMed ID: 15576143
[TBL] [Abstract][Full Text] [Related]
32. [Effects of 1,25-dihydroxyvitamin D3 on the expressions of osteoprotegerin and receptor activator of NF-kappaB ligand in mouse osteoblasts].
Tian QX; Huang GY
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Aug; 26(4):418-22. PubMed ID: 15379268
[TBL] [Abstract][Full Text] [Related]
33. Synthesis of osteoprotegerin and RANKL by megakaryocytes is modulated by oestrogen.
Bord S; Frith E; Ireland DC; Scott MA; Craig JI; Compston JE
Br J Haematol; 2004 Jul; 126(2):244-51. PubMed ID: 15238146
[TBL] [Abstract][Full Text] [Related]
34. Periodontal ligament cells under intermittent tensile stress regulate mRNA expression of osteoprotegerin and tissue inhibitor of matrix metalloprotease-1 and -2.
Tsuji K; Uno K; Zhang GX; Tamura M
J Bone Miner Metab; 2004; 22(2):94-103. PubMed ID: 14999519
[TBL] [Abstract][Full Text] [Related]
35. Osteosclerosis in advanced chronic idiopathic myelofibrosis is associated with endothelial overexpression of osteoprotegerin.
Bock O; Loch G; Schade U; Büsche G; Wasielewski R; Wiese B; Kreipe H
Br J Haematol; 2005 Jul; 130(1):76-82. PubMed ID: 15982347
[TBL] [Abstract][Full Text] [Related]
36. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand system in the early post-operative period of liver transplantation.
Fábrega E; Orive A; García-Unzueta M; Amado JA; Casafont F; Pons-Romero F
Clin Transplant; 2006; 20(3):383-8. PubMed ID: 16824158
[TBL] [Abstract][Full Text] [Related]
37. Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures.
Kaji H; Kanatani M; Sugimoto T; Chihara K
Horm Metab Res; 2005 Oct; 37(10):589-92. PubMed ID: 16278780
[TBL] [Abstract][Full Text] [Related]
38. Tumor necrosis factor-alpha promotes the expression of osteoprotegerin in rheumatoid synovial fibroblasts.
Kubota A; Hasegawa K; Suguro T; Koshihara Y
J Rheumatol; 2004 Mar; 31(3):426-35. PubMed ID: 14994384
[TBL] [Abstract][Full Text] [Related]
39. Vitamin A differentially regulates RANKL and OPG expression in human osteoblasts.
Jacobson A; Johansson S; Branting M; Melhus H
Biochem Biophys Res Commun; 2004 Sep; 322(1):162-7. PubMed ID: 15313187
[TBL] [Abstract][Full Text] [Related]
40. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.
Sordillo EM; Pearse RN
Cancer; 2003 Feb; 97(3 Suppl):802-12. PubMed ID: 12548579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
